SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 2
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 3
    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
  • 4
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
  • 5
    Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-2143.
  • 6
    Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
  • 7
    Molina AM, Feldman DR, Voss MH, et al. Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011; 117: 1868-1876.
  • 8
    Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009; 7: 24-27.
  • 9
    Patnaik A, Ricart A, Cooper JS. A phase 1, pharmacokinetic and pharmacodynamic study of sorafenib, a multitargeted kinase inhibitor, in combination with temsirolimus, an mTOR inhibitor, in patients with advanced solid malignancies [abstract]. J Clin Oncol. 2007; 25( 18 suppl):Page. Abstract 3512.
  • 10
    Merchan JR, Liu G, Fitch T, et al. Phase 1 trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma [abstract]. J Clin Oncol. 2007; 25( 18 suppl):Page. Abstract 5034.
  • 11
    Harzstark AL, Small EJ, Weinberg VK, et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma [published online ahead of print March 8, 2011]. Cancer. doi: 10.1002/cncr.25931.
  • 12
    Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010; 28: 2131-2136.
  • 13
    Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 1432-1439.
  • 14
    Sosman JA, Flaherty K, Atkins MB, et al. Updated results of a phase 1 trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer [abstract]. J Clin Oncol. 2008; 26: PAGE. Abstract 5011.
  • 15
    Semrad TJ, Eddings C, Dutia MP, Christensen S, Lau D, Lara P. Phase 1 study of temsirolimus and pazopanib in solid tumors with emphasis on renal cell carcinoma [abstract]. J Clin Oncol. 2011; 29: PAGE. Abstract e15113.
  • 16
    Escudier B, Negrier S, Gravis G, et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal carcinoma? Results of the randomized TORAVA phase II trial. J Clin Oncol. 2010; 28( 15 suppl): 4516a.
  • 17
    Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010; 28: 207-214.
  • 18
    Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011; 13: 103-111.
  • 19
    Rini BI, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma: results of phase 3 AXIS trial [abstract]. J Clin Oncol. 2011; 29: Page. Abstract 4503.
  • 20
    Merchan JR, Pitot HC, Qin R. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients. J Clin Oncol. 2009; 27: 5039a.
  • 21
    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.